Promontory Therapeutics Announces Preliminary Results from Phase 2 Study of PT-112 Monotherapy in mCRPC to be Presented at the ASCO 2025 Annual Meeting
NEW YORK—April 23, 2025—Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule oncology approaches with immunotherapeutic effects, will present preliminary data from the Phase 2 study of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer at the American Society of Clinical Oncology’s Annual Meeting . ASCO 2025 will be held from May 30 – June 3, 2025 in Chicago, IL.
The poster presentation will include results from the randomized Phase 2 proof of concept and dose optimization study, including safety and efficacy data from the three dosing arms, along with biomarker responses and correlative research.
Poster Session Details
Title: Preliminary phase 2 results of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC)
Location: Hall A, McCormick Place Convention Center, Chicago, Illinois
Poster Board Number: 270
Published Abstract Number: 5071
Session: Genitourinary Cancer - Prostate, Testicular, and Penile
Session date + time: June 2, 2025, 9:00 AM-12:00 PM CDT
For more information about Promontory Therapeutics and PT-112, visit www.PromontoryTx.com.
About Promontory Therapeutics
Promontory Therapeutics Inc. is a privately held, clinical stage drug development company based in New York, focused on small molecules with anti-cancer immune effects. Clinical data generated across six studies of lead molecule PT-112 have demonstrated single-agent and combination anti-cancer activity and an attractive tolerability profile. The Company's lead Phase 2 study in late-stage metastatic castration-resistant prostate cancer patients in the United States and France was the subject of an end of Phase 2 (EOP2) meeting with FDA, with pending regulatory meetings in other jurisdictions. The company applies a borderless collaboration model for research and development work, which has been conducted in the United States, Europe and Asia. As part of its recent clinical expansion into France, Promontory was selected as the first international company member of the Paris-Saclay Cancer Cluster, Europe's emerging biotech hub for oncology. The company also has an active Phase 2 trial underway at the National Cancer Institute (NCI) under a Collaborative Research and Development Agreement (CRADA), assessing PT-112 monotherapy in thymic epithelial tumors (TETs), a rare disease with no FDA approved drug, for which Promontory holds FDA Orphan Drug designation.
CONTACTS:
Promontory Therapeutics
Email: info@promontorytx.com
Media
Alexis Feinberg
Email: promontoryPR@icrhealthcare.com
SOURCE Promontory Therapeutics Inc.